Rezolute (RZLT) Other Operating Expenses (2011 - 2026)
Rezolute recorded quarterly Other Operating Expenses of -$1.5 million in Q1 2026, up 69.79% quarter-over-quarter from -$5.0 million in Q4 2025, and up 19.86% year-over-year from -$1.2 million in Q1 2025.
Rezolute's Other Operating Expenses history runs 11 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Other Operating Expenses rose 19.86% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$11.7 million (down 107.43% YoY), while the FY2025 annual figure was -$7.6 million, down 32.43% from the prior year.
- Other Operating Expenses came in at -$1.5 million for Q1 2026 at Rezolute, up from -$5.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$1.5 million in Q1 2026 to a low of -$5.0 million in Q4 2025.
- A 3-year average of -$2.5 million and a median of -$1.9 million in 2024 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses plunged 167.75% in 2025 and gained 19.86% in 2026, its largest moves.
- Rezolute's Other Operating Expenses stood at -$1.9 million in 2024, then sank by 167.75% to -$5.0 million in 2025, then jumped by 69.79% to -$1.5 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$1.5 million, -$5.0 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.50 Mn |
| Dec 31, 2025 | -4.96 Mn |
| Sep 30, 2025 | -3.32 Mn |
| Jun 30, 2025 | -1.96 Mn |
| Mar 31, 2025 | -1.87 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Dec 31, 2018 | 168,000.00 |
| Sep 30, 2018 | -262,340.00 |
| Jun 30, 2018 | 200,000.00 |
| Sep 30, 2017 | -327,600.00 |
| Jun 30, 2017 | -291,202.00 |
| Mar 31, 2017 | -382,535.00 |
| Dec 31, 2016 | -301,520.00 |
| Sep 30, 2016 | -256,596.00 |
| Jun 30, 2016 | -203,277.00 |
| Mar 31, 2016 | -302,731.00 |
| Dec 31, 2015 | -198,466.00 |
| Sep 30, 2015 | -205,183.00 |
| Jun 30, 2015 | -191,870.00 |
| Mar 31, 2015 | -87,033.00 |
| Dec 31, 2014 | -183,872.00 |
| Sep 30, 2014 | -471,883.00 |
| Jun 30, 2014 | -259,699.00 |
| Mar 31, 2014 | -575,540.00 |
| Dec 31, 2013 | -106,407.00 |
| Sep 30, 2013 | 670,650.00 |
| Jun 30, 2013 | 1.02 Mn |
| Mar 31, 2013 | 4.00 Mn |
| Dec 31, 2012 | 458,296.00 |
| Sep 30, 2012 | 522,079.00 |
| Jun 30, 2012 | 196,680.00 |
| Mar 31, 2012 | 80,604.00 |
| Dec 31, 2011 | 24,500.00 |
| Sep 30, 2011 | -24,500.00 |